Literature DB >> 31991151

Association of blood glucose and renal end points in advanced diabetic kidney disease.

Edy Kornelius1, Shih-Chang Lo2, Chien-Ning Huang1, Yu-Hsun Wang3, Yi-Sun Yang4.   

Abstract

AIMS: The association of blood glucose in advanced diabetic kidney disease (DKD) is unclear. This study investigated the association between blood glucose and renal endpoints in DKD patients.
METHODS: This retrospective cohort study enrolled type 2 diabetic patients with advanced DKD with an estimated glomerular filtration rate (eGFR) between 30 and 90 ml/min/1.73 m2 and urine albumin-to-creatinine ratio (UACR) of 300-5000 mg/g. We classified patients into 2 groups according to their 1-year average HbA1c: <7% and >7%. We followed up the patients until the occurrence of primary renal endpoints.
RESULTS: A total of 345 patients were included in the analysis for the period 2012-2018. Mean baseline eGFR was 58 ml/min/1.73 m2 and mean albuminuria levels were 1146 and 1313 mg/g, respectively. Median study duration was 3 years. The risk of primary renal endpoints was not decreased in patients with HbA1c less than 7% with an adjusted hazard ratio (aHR) of 0.62, 95% CI 0.26-1.45. The risks of persistent eGFR lower than 15 ml/min/1.73 m2 and doubling of serum creatinine level were similar between 2 group with aHR of 0.58 (95% CI 0.19-1.83) and 0.61 (95% CI 0.26-1.44), respectively.
CONCLUSIONS: Intensive blood sugar control did not prevent renal failure in advanced DKD.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Diabetic kidney disease; Glucose; HbA1c; Nephropathy

Mesh:

Substances:

Year:  2020        PMID: 31991151     DOI: 10.1016/j.diabres.2020.108011

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


  1 in total

1.  The Value of Ketone Bodies in the Evaluation of Kidney Function in Patients with Type 2 Diabetes Mellitus.

Authors:  Yimei Li; Yongze Zhang; Ximei Shen; Fengying Zhao; Sunjie Yan
Journal:  J Diabetes Res       Date:  2021-04-10       Impact factor: 4.011

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.